Abstral (AB-stral) is a new fentanyl sublingual tab for breakthrough pain in cancer patients
July 2011
Abstral (AB-stral) is a new fentanyl sublingual tab for breakthrough pain in cancer patients who are opioid tolerant.
It will compete with Onsolis (fentanyl buccal film) once it's available...manufacturing problems have delayed the Onsolis launch.
Make sure Abstral is used ONLY in patients who are opioid tolerant...such as those taking at least 60 mg/day oral morphine or 30 mg/day oxycodone for a week or longer.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive